Lutetium-177 (177Lu) is the radioactive component of 177Lu-PSMA-617. It is classified as a medium-energy beta emitter.Combining enzalutamide with lutetium-177-PSMA-617 for treating metastatic castration-resistant prostate cancer (mCRPC):
Investigating a bit further
More specifically combining enzalutamide with lutetium-177-PSMA-617ENZA-p Trial ResultsThe ENZA-p trial was a phase 2 randomized study comparing enzalutamide alone to enzalutamide plus 177Lu-PSMA-617 in patients with mCRPC. Key results include:Median PSA progression-free survival (PSA-PFS):Combination therapy: 13.0 monthsEnzalutamide alone: 7.8 monthsHazard ratio: 0.43 (95% CI 0.29-0.63, p < 0.0001) PSA response rates: PSA50 (≥50% decrease): 93% for combination vs 68% for enzalutamide alone (p <0 .001)PSA90 (≥ 90% decrease): 78% for combination vs 37% for enzalutamide alone (p < 0.001)Median radiographic PFS:Combination therapy: 16 monthsEnzalutamide alone: 12 monthsHazard ratio: 0.67 (95% CI 0.44-1.01)Safety:Grade 3-5 adverse events: 40% for combination vs 41% for enzalutamide aloneMost common adverse events in combination arm: fatigue (75%), nausea (47%), dry mouth (40%)
Compare...
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045%2824%2900135-9/abstract
CU6 - Media and Industry News, page-227
-
- There are more pages in this discussion • 96 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CU6 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$6.46 |
Change
0.090(1.41%) |
Mkt cap ! $2.013B | |||
| Open | High | Low | Value | Volume |
| $6.40 | $6.50 | $6.13 | $10.02M | 1.580M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 3329 | $6.43 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $6.50 | 45351 | 7 |
View Market Depth
| Last trade - 16.10pm 24/07/2024 (20 minute delay) ? |
| CU6 (ASX) Chart |